{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:15:35Z","timestamp":1784992535094,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Notre Dame Australia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Alopecia is a distressing side-effect of taxane chemotherapy, and evidence suggests that docetaxel leads to chronic alopecia. We measured rates of satisfaction with hair regrowth among women who received adjuvant docetaxel compared with paclitaxel to identify a difference in outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We identified adult female patients who received paclitaxel or docetaxel chemotherapy for early breast cancer from 2010 to 2015. They were screened to ensure they were alive, without metastatic relapse or a new cancer. Eligible participants were sent an introductory letter, consent, a Dermatology Life Quality Index (DLQI) questionnaire, a Visual Analogue Score (VAS) and the European Organisation for Research and Treatment of Cancer (EORTC) general and breast-specific quality of life. The primary outcomes were the DLQI: a 10-item questionnaire scored on a 0\u20133 scale (higher scores indicating distress and dissatisfaction) and the VAS (scored out of 4). Secondary outcomes were the global health status, function, symptom score and breast specific outcomes shown by the EORTC QLQ-C30 and EORTC QLQ-BR23.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 88 responders from 210 letters (response rate 42%); 38 (43%) had docetaxel and 50 (57%) had paclitaxel. They were aged 26\u201390 (median: 59). There was a significant difference in DLQI scores, with the docetaxel group having a higher median score (docetaxel: 4 vs paclitaxel: 1, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). A significantly higher proportion of patients reported no effect of hair loss in the paclitaxel group (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). Similarly, there was a significant difference in VAS scores with the docetaxel group having a higher median score (docetaxel: 1 vs. paclitaxel: 0.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Secondary outcomes did not reach statistical significance. There was no association with aromatase inhibitor exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study shows that adjuvant docetaxel chemotherapy is associated with statistically significant higher rates of dissatisfaction and chronic alopecia than paclitaxel chemotherapy. This supports literature and should be discussed prior to administering docetaxel regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09664-7","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:08:15Z","timestamp":1750655295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey"],"prefix":"10.1007","volume":"33","author":[{"given":"Amy E.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Beith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"9664_CR1","unstructured":"Australia DCfCC. The ROSA Project \u2013 summary. Summary of \u2018Roadmap for Optimising Screening in Australia \u2013 Breast\u2019, investigating risk-based breast cancer screening. 2023."},{"key":"9664_CR2","unstructured":"Australia C. Breast cancer in Australia statistics 2022 [15\/12\/2024]. Available from: https:\/\/www.canceraustralia.gov.au\/cancer-types\/breast-cancer\/statistics."},{"key":"9664_CR3","doi-asserted-by":"crossref","unstructured":"Wilson M, Burke, L, Ferguson, T, Ghersi, D, Nowak, AK, Wilcken, N (2019) Taxanes for adjuvant treatment of early breast cancer (Review). Cochrane Database System Rev (9)","DOI":"10.1002\/14651858.CD004421.pub3"},{"key":"9664_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"M Clark","year":"2005","unstructured":"Clark M, Collins R, Darby S, Davies C, Evans V et al (2005) Effects of chemotherapy and hormonal therapy and 15 year survival: an overview of randomized trials. The Lancet 365:1687\u20131717","journal-title":"The Lancet"},{"issue":"4","key":"9664_CR5","first-page":"e59266","volume":"16","author":"A Jivani","year":"2024","unstructured":"Jivani A, Shinde RK (2024) A comprehensive review of taxane treatment in breast cancer: clinical perspectives and toxicity profiles. Cureus 16(4):e59266","journal-title":"Cureus"},{"key":"9664_CR6","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.3390\/curroncol31090423","volume":"31","author":"A Perez","year":"2024","unstructured":"Perez A, Haberland NL, Miteva M, Wikramanayake TV (2024) Chemotherapy-induced alopecia by docetaxel: prevalence, treatment and prevention. Curr Oncol 31:5709\u20135721","journal-title":"Curr Oncol"},{"issue":"11","key":"9664_CR7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamadermatol.2021.3676","volume":"157","author":"B Bhoyrul","year":"2021","unstructured":"Bhoyrul B, Asfour L, Lutz G, Mitchell L, Jerjen R, Sinclair RD, Holmes S, Chaudhry IH, Harries MJ (2021) Clinicopathologic characteristics and responseto treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol 157(11):1335\u20131342","journal-title":"JAMA Dermatol"},{"key":"9664_CR8","doi-asserted-by":"crossref","unstructured":"Kang D, Kim IR, C EK, Hyuck Y, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. The Oncologist 24:414\u201320","DOI":"10.1634\/theoncologist.2018-0184"},{"key":"9664_CR9","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/annonc\/mds095","volume":"23","author":"N Kluger","year":"2012","unstructured":"Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, Guillot B, Romieu G, Bessis D (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23:2879\u20132884","journal-title":"Ann Oncol"},{"issue":"5","key":"9664_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.21037\/apm-24-69","volume":"13","author":"M Peera","year":"2024","unstructured":"Peera M, Rose L, Kaufman L, Zhang E, Alkhaifi M, Dulmage B (2024) Hair loss: alopecia fears and realities for survivors of breast cancer\u2014a narrative review. Ann Palliat Med 13(5):1235\u20131245","journal-title":"Ann Palliat Med"},{"key":"9664_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/cncr.34732","volume":"129","author":"V Pleasant","year":"2023","unstructured":"Pleasant V, Purkiss AS, Merjaver SD (2023) Redefining the \u201ccrown\u201d: approaching chemotherapy-induced alopecia among Black patients with breast cancer. Cancer 129:1629\u20131633","journal-title":"Cancer"},{"key":"9664_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/XEB.0000000000000051","volume":"13","author":"J Micklem","year":"2015","unstructured":"Micklem J (2015) Self-reported health-related quality-of-life issues for Aboriginal and Torres Strait Islander patients with experience of cancer in Australia: a review of literature. J Evidence-Based Healthcare 13:233\u2013153","journal-title":"J Evidence-Based Healthcare"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09664-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:56:20Z","timestamp":1757195780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09664-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9664"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09664-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"615"}}